104566-43-0

Basic information

• Product Name: 3-BENZYLOXYBENZYLAMINE
• Synonyms: 3-BENZYLOXYBENZYLAMINE;1-[3-(benzyloxy)phenyl]methanamine(SALTDATA: HCl 0.5H2O);[3-(Benzyloxy)benzyl]amine hydrochloride;(3-(benzyloxy)phenyl)methanamine HCl
• CAS NO: 104566-43-0
• Molecular Formula: C₁₄H₁₅NO
• Molecular Weight: 213.27
• Mol File: 104566-43-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-BENZYLOXYBENZYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BENZYLOXYBENZYLAMINE(104566-43-0)
• EPA Substance Registry System: 3-BENZYLOXYBENZYLAMINE(104566-43-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 104566-43-0(Hazardous Substances Data)

Usage

Uses

Due to the limited information available about 3-Benzyloxybenzylamine, its specific applications are not well-defined. However, based on its classification as a benzylether, it can be inferred that it may have potential uses in various industries, such as:
Used in Pharmaceutical Industry:
3-Benzyloxybenzylamine may be used as an intermediate or building block in the synthesis of pharmaceutical compounds. Its unique structure could contribute to the development of new drugs with specific therapeutic properties.
Used in Chemical Research:
In the field of chemical research, 3-Benzyloxybenzylamine could be used as a subject of study to understand its chemical properties, reactivity, and potential interactions with other compounds. This knowledge can be valuable for developing new synthetic routes or applications.
Used in Environmental Science:
3-Benzyloxybenzylamine may have potential applications in environmental science, such as in the development of new materials with specific properties, like biodegradability or pollutant absorption. Further research is needed to explore these possibilities.

Upstream product

• 440105-49-7 1-(azidomethyl)-3-(benzyloxy)benzene 
• 191097-27-5 methanesulfonic acid 3-benzyloxybenzyl ester 
• 620-24-6 3-Hydroxybenzyl alcohol 
• 100-39-0 benzyl bromide 
• 873-62-1 m-cyanophenol 
• 100-44-7 benzyl chloride 
• 61147-43-1 4-cyano-2-benzyloxypyridine 
• 1700-37-4 3-Benzyloxybenzaldehyde 
• 1700-30-7 (3-(benzyloxy)phenyl)methanol 
• 93033-58-0 3-(benzyloxy)benzaldehyde oxime 

Downstream Products

• 440105-50-0 (R)-2-[(tert-butoxycarbonyl)amino]-4-(methylmercapto)-N-[3-(benzyloxy)benzyl]butyramide 
• 1053417-60-9 diethyl 1-(3-benzyloxybenzyl)-1,4-dihydro-4-phenyl-pyridine-3,5-dicarboxylate 
• 1264366-63-3 N-[3-(benzyloxy)benzyl]formamide 
• 1264366-62-2 1-(benzyloxy)-4-(isocyanomethyl)benzene 
• 1264366-71-3 C₃₂H₃₂N₂O₆ 
• 1264366-85-9 N-[(3-benzyloxyphenyl)methyl]-2-(4-methoxyphenyl)-2-{6-methyl-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl}acetamide 
• 1264366-95-1 N-[(3-hydroxyphenyl)methyl]-2-(4-methoxyphenyl)-2-{6-methyl-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl}acetamide 
• 1370459-66-7 (Z)-4-((3-(benzyloxy)benzyl)amino)-2-hydroxy-4-oxobut-2-enoic acid 
• 104566-41-8 3-(benzyloxy)benzylamine hydrochloride 
• 1067234-97-2 6-(3-benzyloxybenzylamino)nicotinic acid 
• 1428535-96-9 (S)-6-oxo-piperidine-2-carboxylic acid ((S)-1-(3-benzyloxy-benzylcarbamoyl)-6-mercapto-hexyl)-amide 
• 1428535-74-3 thioacetic acid S-{(S)-6-(3-benzyloxy-benzylcarbamoyl)-6-[((S)-6-oxo-piperidine-2-carbonyl)-amino]-hexyl} ester 

Relevant articles and documents

COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS

The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.

HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME

The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. The compound has a superior TRPA1 antagonist activity, and can provide a medicament useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.

AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY

Amine compounds having activity against inflammation, fungi, unicellular parasitic microorganisms, and cancer are described. The compounds contain a monocyclic, bicyclic, or tricyclic aromatic ring having one, two, or three ring nitrogen atoms.

Tandem Ugi MCR/mitsunobu cyclization as a short, protecting-group-free route to benzoxazinones with four diversity points

A tandem Ugi/Mitsunobu protocol, starting from o-aminophenols, α-hydroxy acids, amines and aldehydes gives benzo[b][1,4]oxazin-3-ones of general formula 1 in two high-yielding steps, with the introduction of up to four diversity inputs. The mildness of the methodology allows the stereospecific synthesis of enantiomerically pure products as well as the introduction of additional functional groups. The overall procedure can also be carried out in a one-pot manner. A tandem Ugi/Mitsunobu protocol, starting from o-aminophenols and α-hydroxy acids, gives benzo[b][1,4]oxazin-3-ones, with the introduction of up to four diversity inputs, in two high-yielding steps. The procedure may be carried out in a one-pot fashion and has a very broad scope, also allowing the synthesis of enantiomerically pure products.

Novel insight in structure-activity relationship and bioanalysis of P-glycoprotein targeting highly potent tetrakishydroxymethyl substituted 3,9-diazatetraasteranes

Novel 3,9-diazatetraasteranes have been synthesized with varied aromatic substitution patterns and evaluated as P-glycoprotein (P-gp) inhibitors. Structure-activity relationships (SAR) are discussed in relation to determined physicochemical properties. Th

Purinenucleoside derivative modified in 8-position and medical use thereof

The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; RA is a hydrogen atom or a hydroxyl group; R1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R2 to R4, P1 and Q represents a halogen atom, a cyano group or the like.

NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND

Disclosed is an antimalarial agent containing a compound represented by the formula: [wherein A1 represents a 3-pyridyl group that may have a substituent, a 6-quinolyl group that may have a substituent, or the like; X1 represents a group represented by the formula -C(=O)-NH- or the like; E represents a furyl group, a thienyl group or a phenyl group; with the proviso that A1 may have one to three substituents, and E has one of two substituents] or a salt thereof or hydrates thereof.

BENZIMIDAZOLE DERIVATIVES AND MEDICAL USES THEREOF

The present invention providesbenzimidazole derivatives represented by the following formula (I) or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exert an inhibitory activity on sodium-dependent nucleoside transporter 2 and are useful for a disease associated with an abnormality of plasma uric acid level. The compounds of the present invention are useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; R1 and R2 are H, a halogen atom, cyano group, optionally substituted alkyl group, optionally substituted aryl group or the like; R3 is H, a halogen atom, optionally substituted alkyl group or the like; R9 and R5 are H, a halogen atom, OH or the like; and R6 and RX are H or OH: RY is F or OH.

NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND

The present invention provides an antifungal agent represented by the formula: [wherein A1 represents a 3-pyridyl group which may have a substituent, a quinolyl group which may have a substituent, or the like; X1 represents a group represented by the formula -NH-C(=O)-, a group represented by the formula -C(=O)-NH-, or the like; E represents a furyl group, a thienyl group, a pyrrolyl group, a phenyl group, a pyridyl group, a tetrazolyl group, a thiazolyl group or a pyrazolyl group; with the proviso that A1 may have 1 to 3 substituents, and E has one or two substituents].

3-Aminopyrrolidinone farnesyltransferase inhibitors: Design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency

A series of macrocyclic 3-aminopyrrolidinone farnesyltransferase inhibitors (FTIs) has been synthesized. Compared with previously described linear 3-aminopyrrolidinone FTIs such as compound 1, macrocycles such as 49 combined improved pharmacokinetic prope